✦ LIBER ✦

Race impacts outcome in stage III/IV squamous cell carcinomas of the head and neck after concurrent chemoradiation therapy

✍ Scribed by Kathleen Settle; Rodney Taylor; Jeffery Wolf; Young Kwok; Kevin Cullen; Kevin Carter; Robert Ord; Ann Zimrin; Scott Strome; Mohan Suntharalingam

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 273 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24168

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Extent of neck dissection required after

Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma

✍ Steven B. Cannady; Walter T. Lee; Joseph Scharpf; Robert R. Lorenz; Benjamin G. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## Background The management of initially bulky nodal disease after primary nonsurgical treatment for stage IV head and neck squamous cell carcinoma (HNSCC) continues to be a subject of debate. ## Methods A retrospective chart review of neck management in patients after chemoradiatio

Impact of race on outcome after definiti

Impact of race on outcome after definitive radiotherapy for squamous cell carcinoma of the head and neck

✍ Majid O. F. Al-Othman; Christopher G. Morris; Henrietta L. Logan; Russell W. Hin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Background: The objective of the current study was to evaluate the impact of race (black vs. white) on the outcome of patients with invasive squamous cell carcinoma of the head and neck. ## Methods: Between 1983 and 1997, 686 patients completed definitive, twice-daily radiotherapy (rt) alone o

Molecular markers predict outcome in squ

Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation

✍ Guido B. van den Broek; Maarten Wildeman; Coen R.N. Rasch; Nicola Armstrong; Ed 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB

## Abstract Not all patients with squamous cell carcinomas of the head and neck (HNSCC) benefit from concurrent cisplatin‐based chemoradiation, but reliable predictive markers for outcome after chemoradiation are scarce. We have investigated potential prognostic biomarkers for outcome in a large gr

Is concurrent chemoradiation the treatme

Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?

✍ Adam S. Garden; Joshua A. Asper; William H. Morrison; Naomi R. Schechter; Bonnie 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## Abstract ## BACKGROUND Many patients with small primary tumors of the oropharynx have AJCC Stage III/IV disease on the basis of lymphadenopathy. In the current retrospective study, the authors hypothesized that these patients have high rates of locoregional control when treated with radiotherap

Simultaneous combination radiotherapy an

Simultaneous combination radiotherapy and multidrug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck

✍ Bert L. Smith; Jerry L. Franz; Joaquin G. Mira; George A. Gates; J. Sapp; A. B. 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 480 KB

## Abstract Combined simultaneous radiotherapy and multidrug chemotherapy have been utilized in an attempt to eradicate or shrink tumors of the head and neck area in advanced stages to allow subsequent surgical extirpation. Thirty‐six patients (1 stage II; 11 stage III; 24 stage IV; 1 unknown prima

Mature results of a Phase III randomized

Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck

✍ David J. Adelstein; Pierre Lavertu; Jerrold P. Saxton; Michelle Secic; Benjamin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

The current study presents mature results from a Phase III randomized trial comparing radiation therapy and concurrent chemoradiotherapy in patients with resectable American Joint Committee on Cancer Stage III and IV disease.